Novo Nordisk A/S (NVO)
NVO Stock Price Chart
Key Info
| Market Cap | 155.47B |
| Revenue (ttm) | 19.54B |
| Net Income (ttm) | 6.72B |
| Shares Out | 2.36B |
| EPS (ttm) | 2.46 |
| PE Ratio | 27.54 |
| Forward PE | 21.69 |
| Dividend | $1.04 |
| Dividend Yield | 1.53% |
Stock Quote
| Trading Day | December 4 |
| Last Price | $67.81 |
| Previous Close | $67.21 |
| Change ($) | 0.60 |
| Change (%) | 0.89% |
| Day's Open | 67.75 |
| Day's Range | 67.64 - 68.23 |
| Day's Volume | 562,458 |
| 52-Week Range | 49.46 - 73.62 |
NVO Stock News
Bagsværd, Denmark, 4 December 2020 – Novo Nordisk today announced the submission of a new drug application (NDA) to the US Food and Drug Administration (FDA) for subcutaneous semaglutide 2.4 m...
These 7 cheap stocks span industry and have a great chance to appreciate in price next year. Click here for the metrics and reasoning.
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Emispher...
Novo Nordisk A/S (NVO) CEO Lars Jørgensen on ESG Conference Call - Transcript
Let's see if Novo Nordisk A/S (NVO) stock is a good choice for value-oriented investors right now, or if investors subscribing to this methodology should look elsewhere for top picks.
Bagsværd, Denmark, 23 November 2020 – On 3 November 2020, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament ...
Novo Nordisk's (NVO) semaglutide 2.0 mg demonstrates superior reduction in HbA1c versus once-weekly semaglutide 1.0 mg in people with type II diabetes.
Gilead (GILD) and Novo Nordisk present favorable outcomes from a mid-stage study in NASH patients.
Danish pharmaceutical giant Novo Nordisk AS (NYSE:NVO) hopes to apply a unique drug delivery technology it acquired to enable people to take more of its drugs by mouth.
Novo Nordisk, trading near record highs, early Friday announced it would buy a maker of proprietary oral drug delivery technology, a longtime partner, for $1.8 billion, and NVO stock rose. The...
Bagsværd , Denmark, 6 November 202 0 — This document discloses the data of the transaction(s) made in Novo Nordisk shares by the company's board members, executives and their associated person...
ROSELAND, N.J., Nov. 06, 2020 (GLOBE NEWSWIRE) -- Emisphere Technologies, Inc. (“Emisphere” or the “Company”) today announced that it has entered into a definitive agreement with Novo Nordisk ...
Danish diabetes drug maker Novo Nordisk will acquire U.S. Emisphere Technologies, which specialises in developing orally administered versions of drugs, in a deal totalling $1.8 billion, it sa...
Novo Nordisk (NVO) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.
Bagsværd, Denmark, 4 November 2020 — This document discloses the data of the transaction(s) made in Novo Nordisk shares by the company's board members, executives and their associated persons ...
Novo Nordisk A/S purchases B shares worth DKK 2,913 million from Novo Holdings A/S under the 2020 share repurchase programme
Novo Nordisk A/S (NVO) CEO Lars Fruergaard Jorgensen on Q3 2020 Results - Earnings Call Transcript
Novo Nordisk (NVO) misses earnings and sales estimates in the third quarter of 2020.
Novo Nordisk (ETR: NOVC) said on Friday that its net profit in the fiscal third quarter came in better than expected. The company highlighted that patients in Europe and the United States stoc...
30 October 2020 - Financial report for the period 1 January 2020 to 30 September 2020
In light of coronavirus cases increasing both domestically and internationally, four health care companies with strong business quality are Biogen Inc. (NASDAQ:BIIB), Novo Nordisk A/S (NYSE:NV...
Leading wealth managers including BlackRock, Merrill Lynch and Putnam are advising their clients to invest in foreign stocks to take advantage of better values overseas. And the market's best ...
Novo Nordisk (NVO) raises 2020 sales and operating profit outlook at constant exchange rates.
Bagsværd, Denmark, 8 October 2020 – Novo Nordisk today announced that the full-year sales and operating profit outlook at constant exchange rates (CER) has been raised.
With sales growing 8% and net profits growing 12% in the first half of 2020, Novo Nordisk could report solid numbers.
The company's value chain may have been shaken by Covid-19 but it wasn't broken, so Novo Nordisk stock holders should stay invested. The post Hold Novo Nordisk Shares for Consistent Internatio...
As the world grapples with an unprecedented coronavirus pandemic, five health care stocks that have outperformed the Standard & Poor's 500 Index by at least 5% in the year to date are Amerisou...
WASHINGTON, Sept. 10, 2020 /PRNewswire/ -- The American College of Cardiology, in partnership with Novo Nordisk Inc.
The healthcare industry has historically delivered market-beating returns. And the current pandemic has created new opportunities in the sector.
SEATTLE, Aug. 24, 2020 /PRNewswire/ -- UNITED STATES DISTRICT COURT DISTRICT OF NEW JERSEY In re NOVO NORDISK SECURITIES LITIGATION Master File No.
Novo Nordisk shows improving price performance, earning an upgrade to its IBD Relative Strength Rating The post Novo Nordisk Getting Closer To Key Technical Measure appeared first on Investor'...
The Danish multinational offers an exciting growth opportunity.
Novo Nordisk: Long-Term Growth By CV Risk Factor Reduction
Novo Nordisk (NVO) resumes the phase III studies on concizumabin in hemophilia A and B patients regardless of inhibitor status.
DexCom, Tandem Diabetes, and Novo Nordisk have plenty of momentum and growth ahead, making them excellent buys this month.
The biotech sector had a troubled Q2, as doctor visits were curtailed and new Rx'es were in short supply; R&D efforts were also harmed.
Novo Nordisk A/S (NVO) CEO Lars Fruergaard Jorgensen on Q2 2020 Results - Earnings Call Transcript
Novo Nordisk posts second-quarter profit rise, CEO 'optimistic' about weathering virus impacts
Lars Fruergaard Jørgensen, CEO of Novo Nordisk, discusses the company's half-year results and the impacts of the pandemic on the business.
Novo Nordisk's (NVO) earnings surpass estimates but revenues miss the same in the second quarter of 2020.
Novo Nordisk (ETR: NOVC) said on Thursday that its net profit in the fiscal second quarter came in stronger than what the experts had forecast. The company said that destocking and fewer new p...
Financial report for the period 1 January 2020 to 30 June 2020
Among the largest publicly traded pharmaceutical companies, Novo Nordisk (NYSE:NVO) and Roche (RHHBY) had the highest returns on invested capital during the period from 2011 to 2019, according...
Lancet editor: Hope to have Covid-19 vaccine next year
Richard Horton, editor-in-chief of The Lancet, discusses the outlook for a Covid-19 vaccine.
There’s a select group of pharmaceutical stocks that stand to win without even looking for a Covid-19 cure. The post The 7 Best Pharmaceutical Stocks That Go Beyond the Covid-19 Chase appeare...
Shares of Novo Nordisk (NVO) rally on solid product portfolio aided by new approvals.
In light of Novavax Inc. (NASDAQ:NVAX) getting $1.6 billion in federal aid for its coronavirus vaccine candidate, investors might find opportunities in biotechnology stocks that have high fina...
About NVO
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharmaceuticals. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company has a... [Read more...]
| Industry Biotechnology | Founded 1923 |
| CEO Lars Fruergaard Joergensen | Employees 44,326 |
| Stock Exchange NYSE | Ticker Symbol NVO |
Financial Performance
In 2019, NVO's revenue was 122.02 billion, an increase of 9.11% compared to the previous year's 111.83 billion. Earnings were 38.95 billion, an increase of 0.84%.
Analyst Forecasts
According to 4 analysts, the average rating for NVO stock is "Buy." The 12-month stock price forecast is 75.06, which is an increase of 10.69% from the latest price.